Despite these data that suggest BRAFV600 mutations are heterogeneous, the clinical response to BRAF inhibitors is homogenous [1, 2] and suggests that the BRAFV600 mutation is relevant in the majority of melanoma cells. Here, BRAF is linked to melanoma.